Clinical trials: Docetaxel, completed
Breast Neoplasm
Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC
We want to compare Taxol given weekly with Taxotere given every 3 week both in comination with Xeloda. We are going to compare time to treatment failure and quality of life.
- Trial name
- NCT00201435
- Testing
- Paclitaxel weekly in combination with capecitabine, Docetaxel every 3 week in combination with capecitabine
- Where
- Norway
- Volunteers
- 224 people
- Sponsor
- Norwegian Breast Cancer Group
Non-small Cell Lung Carcinoma
Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy
This is a prospective phase II trial, in patients with unresectable or metastatic NSCLC using chemotherapy regimens which will be defined according to the mRNA expression of ERCC1 and RRM1 of the tumor cells.
- Trial name
- NCT01648517
- Testing
- chemotherapy
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Non-Small Cell Lung Cancer
An Open, Randomized, Multicentre, Phase II Pilot Study
The objective of this study is to evaluate efficacy, safety and quality of life adjuvant docetaxel-cisplatin chemotherapy versus no adjuvant treatment in patients with completely resected NSCLC Stage I-II.
- Trial name
- NCT00293085
- Testing
- Docetaxel
- Volunteers
- 37 people
- Sponsor
- Central European Cooperative Oncology Group
Breast Cancer
ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment
The purpose of this study is to compare disease free survival of elderly breast cancer patients treated with standard adjuvant chemotherapy (CMF) versus experimental adjuvant chemotherapy (weekly docetaxel).
- Trial name
- NCT00331097
- Testing
- docetaxel, cyclophosphamide, methotrexate
- Where
- 8 sites in Italy
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute, Naples
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of pasireotide and to see how well it works when given together with docetaxel and prednisone in treating patients with metastatic hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01468532
- Testing
- docetaxel, pasireotide, prednisone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Triple-Negative Breast Cancer
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Both DCb (docetaxel/carboplatin) and EC followed by D (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline.
- Trial name
- NCT03154749
- Testing
- DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Guangdong Provincial People's Hospital
Non-Small Cell Lung Cancer
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
This is an open-label, single institution, phase II study of Sorafenib in combination with docetaxel and carboplatin in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00647426
- Testing
- Sorafenib + Docetaxel/Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Neoplasm
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)
The purpose of this study is to evaluate, in a first stage, the safety (incidence of cardiac toxicity) of Caelyx in combination with Trastuzumab and Docetaxel; and in a second stage, the tumor response rate of this regimen.
- Trial name
- NCT00687440
- Testing
- Pegylated Liposomal Doxorubicin, Docetaxel, Trastuzumab
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without…
- Conditions
- HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
- Trial name
- NCT02605915
- Testing
- Atezolizumab, Carboplatin, Docetaxel
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
Ovarian Neoplasms
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
The purpose of this study is to assess the efficacy and the safety of the treatment.
- Trial name
- Tax-Over (NCT00772863)
- Testing
- docetaxel and cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Sanofi
Primary Breast Cancer
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
The purpose of this study is to optimize results in neoadjuvant chemotherapy of local advanced primary breast cancer. Therefore patients become first 3 cycles of Epirubicin/Docetaxel followed by 3x Carboplatin/Docetaxel.
- Trial name
- ETCat01 (NCT00527449)
- Testing
- Epirubicin, Carboplatin, Docetaxel
- Where
- 3 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Klinikum Weissenfels
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
Bevacizumab is a monoclonal antibody currently used for the treatment of colorectal cancer. It works by preventing the formation of new blood vessels (angiogenesis).
- Trial name
- NCT01025349
- Testing
- Bevacizumab, docetaxel, cisplatin
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Medical University Hospital
Soft Tissue Sarcoma
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival.
- Trial name
- NCT03449901
- Testing
- pegylated arginine deiminase, Gemcitabine, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Lung Cancer
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT05137067
- Testing
- Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Optimal Health Research
Breast Cancer
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of…
- Trial name
- NCT00950300
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 106 sites in Argentina, Brazil and 24 more
- Volunteers
- 596 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00720304
- Testing
- docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC.
- Trial name
- NCT02392455
- Testing
- treatment
- Where
- Germany
- Volunteers
- 817 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00278460
- Testing
- docetaxel, gemcitabine hydrochloride
- Volunteers
- 49 people
- Sponsor
- Wake Forest University Health Sciences
Stage II-III Non-small Cell Lung Cancer
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
This is a randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy versus…
- Trial name
- NCT04158440
- Testing
- 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
- Where
- China
- Volunteers
- 501 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.